Drug Description in Trials / DrugBank / KEGG DRUG

  

Search results

No. 薬物名（臨床試験情報から抽出） DrugBank KEGG DRUG KEGG GENES KEGG PATHWAY 指定難病告示番号
1[rituximab]
(D02994)		1件: Rituximab1件: Rituximab (D02994) 💬 1件: MS4A1 💬 1件: Hematopoietic cell lineage 💬2件: 11, 14 💬
2Abatacept, rituximab or tocilizumab
(D02994)		3件: Abatacept,
Rituximab,
Tocilizumab		3件: Tocilizumab ,
Rituximab (D02994),
Abatacept 💬 		4件: CD80,
CD86,
IL6R,
MS4A1 💬 		25件: Allograft rejection, Autoimmune thyroid disease, Cell adhesion molecule (CAM) interaction, Coronavirus disease, Cytokine-cytokine receptor interaction, Graft-versus-host disease, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, IgSF CAM signaling, Intestinal immune network for IgA production, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Rheumatoid arthritis, Systemic lupus erythematosus, Th17 cell differentiation, Toll-like receptor signaling pathway, Transcriptional misregulation in cancer, Type I diabetes mellitus, Viral myocarditis, Viral protein interaction with cytokine and cytokine receptor, Virion - Adenovirus 💬1件: 46 💬
3ABP 798 - Biosimilar to rituximab
(D02994)		1件: Rituximab1件: Rituximab (D02994) 💬 1件: MS4A1 💬 1件: Hematopoietic cell lineage 💬1件: 46 💬
4ABP 798 Biosimilar to Rituximab
(D02994)		1件: Rituximab1件: Rituximab (D02994) 💬 1件: MS4A1 💬 1件: Hematopoietic cell lineage 💬1件: 46 💬
5Addition of rituximab if recurrence
(D02994)		1件: Rituximab1件: Rituximab (D02994) 💬 1件: MS4A1 💬 1件: Hematopoietic cell lineage 💬1件: 11 💬
6Administration of rituximab and methylprednisolone
(D02994)		2件: Methylprednisolone,
Rituximab		3件: Methylprednisolone ,
Methylprednisolone acetate ,
Rituximab (D02994) 💬 		2件: MS4A1,
NR3C1 💬 		2件: Hematopoietic cell lineage, Neuroactive ligand-receptor interaction 💬1件: 51 💬
7Alemtuzumab and Rituximab
(D02994)		2件: Alemtuzumab,
Rituximab		2件: Alemtuzumab ,
Rituximab (D02994) 💬 		1件: MS4A1 💬 1件: Hematopoietic cell lineage 💬1件: 60 💬
8Alemtuzumab, Rituximab
(D02994)		2件: Alemtuzumab,
Rituximab		2件: Alemtuzumab ,
Rituximab (D02994) 💬 		1件: MS4A1 💬 1件: Hematopoietic cell lineage 💬1件: 63 💬
9Anti-CD20 therapies (Ocrelizumab, Rituximab, Ofatumumab)
(D02994)		3件: Ocrelizumab,
Ofatumumab,
Rituximab		3件: Rituximab (D02994),
Ocrelizumab ,
Ofatumumab 💬 		1件: MS4A1 💬 1件: Hematopoietic cell lineage 💬1件: 13 💬
10Belimumab in SLE patients / Rituximab in RA patients
(D02994)		2件: Belimumab,
Rituximab		2件: Rituximab (D02994),
Belimumab 💬 		2件: MS4A1,
TNFSF13B 💬 		5件: Cytokine-cytokine receptor interaction, Hematopoietic cell lineage, Intestinal immune network for IgA production, NF-kappa B signaling pathway, Rheumatoid arthritis 💬2件: 46, 49 💬
11Bendamustine, Rituximab
(D02994)		2件: Bendamustine,
Rituximab		4件: Rituximab (D02994),
Bendamustine hydrochloride ,
Bendamustine ,
Bendamustine hydrochloride hydrate 💬 		1件: MS4A1 💬 1件: Hematopoietic cell lineage 💬1件: 61 💬
12Combination of Protein A Immunoadsorption, Rituximab, Dexamethasone plus Azathioprine
(D02994)		3件: Azathioprine,
Dexamethasone,
Rituximab		6件: Azathioprine ,
Dexamethasone ,
Dexamethasone sodium phosphate ,
Rituximab (D02994),
Azathioprine sodium ,
Dexamethasone phosphate 💬 		2件: MS4A1,
NR3C1 💬 		2件: Hematopoietic cell lineage, Neuroactive ligand-receptor interaction 💬1件: 35 💬
13Combination of Rituximab
(D02994)		1件: Rituximab1件: Rituximab (D02994) 💬 1件: MS4A1 💬 1件: Hematopoietic cell lineage 💬1件: 63 💬
14Combination of Rituximab with subcutaneous belimumab
(D02994)		2件: Belimumab,
Rituximab		2件: Rituximab (D02994),
Belimumab 💬 		2件: MS4A1,
TNFSF13B 💬 		5件: Cytokine-cytokine receptor interaction, Hematopoietic cell lineage, Intestinal immune network for IgA production, NF-kappa B signaling pathway, Rheumatoid arthritis 💬1件: 63 💬
15Combined Plasma Exchange (PEX), Rituximab, and Corticosteroids
(D02994)		1件: Rituximab1件: Rituximab (D02994) 💬 1件: MS4A1 💬 1件: Hematopoietic cell lineage 💬1件: 85 💬
16Cyclophosphamide/Rituximab
(D02994)		2件: Cyclophosphamide,
Rituximab		3件: Cyclophosphamide ,
Rituximab (D02994),
Cyclophosphamide 💬 		1件: MS4A1 💬 1件: Hematopoietic cell lineage 💬1件: 13 💬
17Dexamethasone and Rituximab
(D02994)		2件: Dexamethasone,
Rituximab		4件: Dexamethasone ,
Dexamethasone sodium phosphate ,
Rituximab (D02994),
Dexamethasone phosphate 💬 		2件: MS4A1,
NR3C1 💬 		2件: Hematopoietic cell lineage, Neuroactive ligand-receptor interaction 💬1件: 63 💬
18Diagnostic Test: Zirconium Zr 89 labelled rituximab
(D02994)		1件: Rituximab1件: Rituximab (D02994) 💬 1件: MS4A1 💬 1件: Hematopoietic cell lineage 💬1件: 41 💬
19Double-Blind Rituximab
(D02994)		1件: Rituximab1件: Rituximab (D02994) 💬 1件: MS4A1 💬 1件: Hematopoietic cell lineage 💬1件: 51 💬
20Dr. Reddy’s Rituximab (DRL_RI) 100mg
(D02994)		1件: Rituximab1件: Rituximab (D02994) 💬 1件: MS4A1 💬 1件: Hematopoietic cell lineage 💬1件: 46 💬
21Dr. Reddy’s Rituximab (DRL_RI) 500mg
(D02994)		1件: Rituximab1件: Rituximab (D02994) 💬 1件: MS4A1 💬 1件: Hematopoietic cell lineage 💬1件: 46 💬
22Eltrombopag combining rituximab
(D02994)		2件: Eltrombopag,
Rituximab		3件: Rituximab (D02994),
Eltrombopag olamine ,
Eltrombopag choline 💬 		2件: MPL,
MS4A1 💬 		4件: Cytokine-cytokine receptor interaction, Hematopoietic cell lineage, Hormone signaling, JAK-STAT signaling pathway 💬1件: 63 💬
23Etanercepet, Rituximab, Abatacept, Tocilizumab, Sarilumab
(D02994)		4件: Abatacept,
Rituximab,
Sarilumab,
Tocilizumab		4件: Tocilizumab ,
Rituximab (D02994),
Abatacept ,
Sarilumab 💬 		4件: CD80,
CD86,
IL6R,
MS4A1 💬 		25件: Allograft rejection, Autoimmune thyroid disease, Cell adhesion molecule (CAM) interaction, Coronavirus disease, Cytokine-cytokine receptor interaction, Graft-versus-host disease, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, IgSF CAM signaling, Intestinal immune network for IgA production, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Rheumatoid arthritis, Systemic lupus erythematosus, Th17 cell differentiation, Toll-like receptor signaling pathway, Transcriptional misregulation in cancer, Type I diabetes mellitus, Viral myocarditis, Viral protein interaction with cytokine and cytokine receptor, Virion - Adenovirus 💬1件: 46 💬
24Experimental (Non Immunosuppressive Symptomatic Treatment (NIST) and Rituximab)
(D02994)		1件: Rituximab1件: Rituximab (D02994) 💬 1件: MS4A1 💬 1件: Hematopoietic cell lineage 💬1件: 222 💬
25GP2013 - A Proposed biosimilar rituximab
(D02994)		1件: Rituximab1件: Rituximab (D02994) 💬 1件: MS4A1 💬 1件: Hematopoietic cell lineage 💬1件: 46 💬
26Higher Dose of Rituximab
(D02994)		1件: Rituximab1件: Rituximab (D02994) 💬 1件: MS4A1 💬 1件: Hematopoietic cell lineage 💬1件: 63 💬
27IDEC-C2B8 (rituximab)
(D02994)		1件: Rituximab1件: Rituximab (D02994) 💬 1件: MS4A1 💬 1件: Hematopoietic cell lineage 💬1件: 46 💬
28Immunosuppressive treatment (eg, rituximab)
(D02994)		1件: Rituximab1件: Rituximab (D02994) 💬 1件: MS4A1 💬 1件: Hematopoietic cell lineage 💬1件: 64 💬
29Individualized dose of rituximab
(D02994)		1件: Rituximab1件: Rituximab (D02994) 💬 1件: MS4A1 💬 1件: Hematopoietic cell lineage 💬1件: 49 💬
30Interferons, glatiramer acetate, teriflunomide, dimethyl fumarate, alemtuzumab, cladribine, fingolimod, ponesimod, rituximab, ocrelizumab, ofatumumab, natalizumab
(D02994)		12件: Acetate,
Alemtuzumab,
Cladribine,
Dimethyl fumarate,
Fingolimod,
Glatiramer,
Natalizumab,
Ocrelizumab,
Ofatumumab,
Ponesimod,
Rituximab,
Teriflunomide		13件: Cladribine ,
Alemtuzumab ,
Rituximab (D02994),
Dimethyl fumarate ,
Fingolimod hydrochloride ,
Glatiramer acetate ,
Ocrelizumab ,
Natalizumab ,
Ofatumumab ,
Fingolimod ,
Teriflunomide ,
Ponesimod ,
Fingolimod lauryl sulfate 💬 		26件: DHODH,
HLA-A,
HLA-B,
HLA-C,
HLA-DMA,
HLA-DMB,
HLA-DOA,
HLA-DOB,
HLA-DPA1,
HLA-DPB1,
HLA-DQA1,
HLA-DQA2,
HLA-DQB1,
HLA-DRA,
HLA-DRB1,
HLA-DRB3,
HLA-DRB4,
HLA-DRB5,
HLA-E,
HLA-F,
HLA-G,
ITGA4,
KEAP1,
MS4A1,
RRM1,
S1PR1 💬 		58件: Allograft rejection, Antigen processing and presentation, Arrhythmogenic right ventricular cardiomyopathy, Asthma, Autoimmune thyroid disease, Cell adhesion molecule (CAM) interaction, Cellular senescence, Chemical carcinogenesis - reactive oxygen species, Cytoskeleton in muscle cells, Dilated cardiomyopathy, Drug metabolism - other enzymes, ECM-receptor interaction, Efferocytosis, Endocytosis, Epstein-Barr virus infection, Fluid shear stress and atherosclerosis, Focal adhesion, FoxO signaling pathway, Glutathione metabolism, Graft-versus-host disease, Hematopoietic cell lineage, Hepatocellular carcinoma, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IgSF CAM signaling, Inflammatory bowel disease, Influenza A, Integrin signaling, Intestinal immune network for IgA production, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Leukocyte transendothelial migration, Natural killer cell mediated cytotoxicity, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway, Parkinson disease, Pathways in cancer, Phagocytosis, Purine metabolism, Pyrimidine metabolism, Regulation of actin cytoskeleton, Rheumatoid arthritis, Sphingolipid signaling pathway, Staphylococcus aureus infection, Systemic lupus erythematosus, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Ubiquitin mediated proteolysis, Viral carcinogenesis, Viral myocarditis, Yersinia infection 💬1件: 13 💬
31Intravenous Rituximab
(D02994)		1件: Rituximab1件: Rituximab (D02994) 💬 1件: MS4A1 💬 1件: Hematopoietic cell lineage 💬1件: 66 💬
32Low-dose rituximab
(D02994)		1件: Rituximab1件: Rituximab (D02994) 💬 1件: MS4A1 💬 1件: Hematopoietic cell lineage 💬1件: 63 💬
33MabionCD20 (candidate biosimilar to rituximab)
(D02994)		1件: Rituximab1件: Rituximab (D02994) 💬 1件: MS4A1 💬 1件: Hematopoietic cell lineage 💬1件: 46 💬
34MabThera (Rituximab)
(D02994)		1件: Rituximab1件: Rituximab (D02994) 💬 1件: MS4A1 💬 1件: Hematopoietic cell lineage 💬4件: 13, 46, 49, 53 💬
35Mabthera or biosimilar Rituximab
(D02994)		1件: Rituximab1件: Rituximab (D02994) 💬 1件: MS4A1 💬 1件: Hematopoietic cell lineage 💬2件: 48, 61 💬
36Mabthera or biosimilar rituximab product
(D02994)		1件: Rituximab1件: Rituximab (D02994) 💬 1件: MS4A1 💬 1件: Hematopoietic cell lineage 💬1件: 13 💬
37MabThera® (rituximab)
(D02994)		1件: Rituximab1件: Rituximab (D02994) 💬 1件: MS4A1 💬 1件: Hematopoietic cell lineage 💬1件: 46 💬
38Originator rituximab - Rituxan ® or MabThera ®
(D02994)		1件: Rituximab1件: Rituximab (D02994) 💬 1件: MS4A1 💬 1件: Hematopoietic cell lineage 💬1件: 46 💬
39Other: Natalizumab/natalizumab-sztn, Alemtuzumab, Ocrelizumab, Rituximab/rituximab-arrx/rituximab-abbs/rituximab-pvvr, Cladribine, Ofatumumab, Ublituximab-xiiy, Ocrelizumab and hyaluronidase-ocsq
(D02994)		8件: Alemtuzumab,
Cladribine,
Hyaluronidase,
Natalizumab,
Ocrelizumab,
Ofatumumab,
Rituximab,
Ublituximab		10件: Cladribine ,
Alemtuzumab ,
Rituximab (D02994),
Hyaluronidase ,
Hyaluronidase ,
Ocrelizumab ,
Hyaluronidase ,
Natalizumab ,
Ofatumumab ,
Ublituximab 💬 		3件: ITGA4,
MS4A1,
RRM1 💬 		21件: Arrhythmogenic right ventricular cardiomyopathy, Cell adhesion molecule (CAM) interaction, Cytoskeleton in muscle cells, Dilated cardiomyopathy, Drug metabolism - other enzymes, ECM-receptor interaction, Focal adhesion, Glutathione metabolism, Hematopoietic cell lineage, Human papillomavirus infection, Hypertrophic cardiomyopathy, IgSF CAM signaling, Integrin signaling, Intestinal immune network for IgA production, Leishmaniasis, Leukocyte transendothelial migration, PI3K-Akt signaling pathway, Purine metabolism, Pyrimidine metabolism, Regulation of actin cytoskeleton, Yersinia infection 💬1件: 13 💬
40Perfusion of treatment Rituximab
(D02994)		1件: Rituximab1件: Rituximab (D02994) 💬 1件: MS4A1 💬 1件: Hematopoietic cell lineage 💬1件: 13 💬
41Prednisone, low dose rituximab
(D02994)		2件: Prednisone,
Rituximab		2件: Prednisone ,
Rituximab (D02994) 💬 		2件: MS4A1,
NR3C1 💬 		2件: Hematopoietic cell lineage, Neuroactive ligand-receptor interaction 💬1件: 61 💬
42RhTPO in combination with Rituximab
(D02994)		1件: Rituximab1件: Rituximab (D02994) 💬 1件: MS4A1 💬 1件: Hematopoietic cell lineage 💬1件: 63 💬
43Rituxan (INN: Rituximab), brand name in the United States
(D02994)		1件: Rituximab1件: Rituximab (D02994) 💬 1件: MS4A1 💬 1件: Hematopoietic cell lineage 💬1件: 46 💬
44Rituxan (INN: Rituximab), brand name in the US
(D02994)		1件: Rituximab1件: Rituximab (D02994) 💬 1件: MS4A1 💬 1件: Hematopoietic cell lineage 💬1件: 46 💬
45Rituxan (rituximab)
(D02994)		1件: Rituximab1件: Rituximab (D02994) 💬 1件: MS4A1 💬 1件: Hematopoietic cell lineage 💬1件: 49 💬
46Rituxan® (rituximab)
(D02994)		1件: Rituximab1件: Rituximab (D02994) 💬 1件: MS4A1 💬 1件: Hematopoietic cell lineage 💬1件: 46 💬
47RITUXIMAB
(D02994)		1件: Rituximab1件: Rituximab (D02994) 💬 1件: MS4A1 💬 1件: Hematopoietic cell lineage 💬54件: 11, 13, 14, 19, 26, 34, 35, 36, 40, 41, 42, 43, 44, 45, 46, 48, 49, 50, 51, 52, 53, 55, 56, 60, 61, 62, 63, 64, 65, 66, 83, 84, 85, 86, 88, 93, 94, 96, 97, 162, 172, 222, 223, 229, 256, 271, 274, 283, 284, 285, 288, 296, 300, 331 💬
48Rituximab (active comparator)
(D02994)		1件: Rituximab1件: Rituximab (D02994) 💬 1件: MS4A1 💬 1件: Hematopoietic cell lineage 💬1件: 46 💬
49Rituximab (anti-CD20)
(D02994)		1件: Rituximab1件: Rituximab (D02994) 💬 1件: MS4A1 💬 1件: Hematopoietic cell lineage 💬1件: 53 💬
50Rituximab (Arm A)
(D02994)		1件: Rituximab1件: Rituximab (D02994) 💬 1件: MS4A1 💬 1件: Hematopoietic cell lineage 💬2件: 43, 44 💬
51Rituximab (Arm B)
(D02994)		1件: Rituximab1件: Rituximab (D02994) 💬 1件: MS4A1 💬 1件: Hematopoietic cell lineage 💬3件: 43, 44, 63 💬
52Rituximab (EU)
(D02994)		1件: Rituximab1件: Rituximab (D02994) 💬 1件: MS4A1 💬 1件: Hematopoietic cell lineage 💬1件: 46 💬
53Rituximab (genetical recombination)
(D02994)		1件: Rituximab1件: Rituximab (D02994) 💬 1件: MS4A1 💬 1件: Hematopoietic cell lineage 💬3件: 14, 222, 223 💬
54Rituximab (MABTHERA and BIOSIMILARS)
(D02994)		1件: Rituximab1件: Rituximab (D02994) 💬 1件: MS4A1 💬 1件: Hematopoietic cell lineage 💬2件: 35, 162 💬
55Rituximab (Mabthera ®) Belimumab (Benlysta ®)
(D02994)		2件: Belimumab,
Rituximab		2件: Rituximab (D02994),
Belimumab 💬 		2件: MS4A1,
TNFSF13B 💬 		5件: Cytokine-cytokine receptor interaction, Hematopoietic cell lineage, Intestinal immune network for IgA production, NF-kappa B signaling pathway, Rheumatoid arthritis 💬1件: 63 💬
56Rituximab (Mabthera)
(D02994)		1件: Rituximab1件: Rituximab (D02994) 💬 1件: MS4A1 💬 1件: Hematopoietic cell lineage 💬2件: 14, 63 💬
57Rituximab (MABTHERA® or RITUXAN®).
(D02994)		1件: Rituximab1件: Rituximab (D02994) 💬 1件: MS4A1 💬 1件: Hematopoietic cell lineage 💬3件: 35, 61, 63 💬
58Rituximab (Mabthera®)
(D02994)		1件: Rituximab1件: Rituximab (D02994) 💬 1件: MS4A1 💬 1件: Hematopoietic cell lineage 💬1件: 61 💬
59Rituximab (R)
(D02994)		1件: Rituximab1件: Rituximab (D02994) 💬 1件: MS4A1 💬 1件: Hematopoietic cell lineage 💬3件: 13, 43, 44 💬
60Rituximab (Rituxan)
(D02994)		1件: Rituximab1件: Rituximab (D02994) 💬 1件: MS4A1 💬 1件: Hematopoietic cell lineage 💬1件: 11 💬
61Rituximab (RTX) and Azathioprine (AZA)
(D02994)		2件: Azathioprine,
Rituximab		3件: Azathioprine ,
Rituximab (D02994),
Azathioprine sodium 💬 		1件: MS4A1 💬 1件: Hematopoietic cell lineage 💬1件: 65 💬
62Rituximab (US)
(D02994)		1件: Rituximab1件: Rituximab (D02994) 💬 1件: MS4A1 💬 1件: Hematopoietic cell lineage 💬1件: 46 💬
63Rituximab - MabThera
(D02994)		1件: Rituximab1件: Rituximab (D02994) 💬 1件: MS4A1 💬 1件: Hematopoietic cell lineage 💬1件: 46 💬
64Rituximab 1g IV
(D02994)		1件: Rituximab1件: Rituximab (D02994) 💬 1件: MS4A1 💬 1件: Hematopoietic cell lineage 💬1件: 162 💬
65Rituximab 1g/6months
(D02994)		1件: Rituximab1件: Rituximab (D02994) 💬 1件: MS4A1 💬 1件: Hematopoietic cell lineage 💬1件: 46 💬
66Rituximab 200mg/6months
(D02994)		1件: Rituximab1件: Rituximab (D02994) 💬 1件: MS4A1 💬 1件: Hematopoietic cell lineage 💬1件: 46 💬
67Rituximab [MabThera/Rituxan]
(D02994)		1件: Rituximab1件: Rituximab (D02994) 💬 1件: MS4A1 💬 1件: Hematopoietic cell lineage 💬2件: 46, 63 💬
68Rituximab [MabThera]
(D02994)		1件: Rituximab1件: Rituximab (D02994) 💬 1件: MS4A1 💬 1件: Hematopoietic cell lineage 💬1件: 46 💬
69Rituximab and Cyclophosphamide IV
(D02994)		2件: Cyclophosphamide,
Rituximab		3件: Cyclophosphamide ,
Rituximab (D02994),
Cyclophosphamide 💬 		1件: MS4A1 💬 1件: Hematopoietic cell lineage 💬1件: 35 💬
70Rituximab and dexamethasone
(D02994)		2件: Dexamethasone,
Rituximab		4件: Dexamethasone ,
Dexamethasone sodium phosphate ,
Rituximab (D02994),
Dexamethasone phosphate 💬 		2件: MS4A1,
NR3C1 💬 		2件: Hematopoietic cell lineage, Neuroactive ligand-receptor interaction 💬1件: 63 💬
71Rituximab and Hyaluronidase Human
(D02994)		2件: Hyaluronidase,
Rituximab		4件: Rituximab (D02994),
Hyaluronidase ,
Hyaluronidase ,
Hyaluronidase 💬 		1件: MS4A1 💬 1件: Hematopoietic cell lineage 💬1件: 331 💬
72Rituximab Biosimilar
(D02994)		1件: Rituximab1件: Rituximab (D02994) 💬 1件: MS4A1 💬 1件: Hematopoietic cell lineage 💬1件: 222 💬
73Rituximab Biosimilar ABP 798
(D02994)		1件: Rituximab1件: Rituximab (D02994) 💬 1件: MS4A1 💬 1件: Hematopoietic cell lineage 💬1件: 222 💬
74Rituximab combined with corticosteroids
(D02994)		1件: Rituximab1件: Rituximab (D02994) 💬 1件: MS4A1 💬 1件: Hematopoietic cell lineage 💬1件: 222 💬
75Rituximab combined with Daratumumab(Anti-CD38 Monoclonal Antibody)
(D02994)		2件: Daratumumab,
Rituximab		2件: Rituximab (D02994),
Daratumumab 💬 		2件: CD38,
MS4A1 💬 		6件: Calcium signaling pathway, Hematopoietic cell lineage, Nicotinate and nicotinamide metabolism, Oxytocin signaling pathway, Pancreatic secretion, Salivary secretion 💬1件: 63 💬
76Rituximab combined with Omalizumab
(D02994)		2件: Omalizumab,
Rituximab		2件: Rituximab (D02994),
Omalizumab 💬 		2件: FCER1A,
MS4A1 💬 		5件: Asthma, Fc epsilon RI signaling pathway, Hematopoietic cell lineage, Phospholipase D signaling pathway, Sphingolipid signaling pathway 💬1件: 162 💬
77Rituximab combined with tacrolimus induction + rituximab maintenance
(D02994)		2件: Rituximab,
Tacrolimus		3件: Tacrolimus ,
Rituximab (D02994),
Tacrolimus 💬 		6件: MS4A1,
PPP3CA,
PPP3CB,
PPP3CC,
PPP3R1,
PPP3R2 💬 		34件: Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis, Axon guidance, B cell receptor signaling pathway, C-type lectin receptor signaling pathway, Calcium signaling pathway, Cellular senescence, Dopaminergic synapse, Glucagon signaling pathway, Glutamatergic synapse, Hematopoietic cell lineage, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Lipid and atherosclerosis, Long-term potentiation, MAPK signaling pathway, Natural killer cell mediated cytotoxicity, Oocyte meiosis, Osteoclast differentiation, Oxytocin signaling pathway, PD-L1 expression and PD-1 checkpoint pathway in cancer, Pathways of neurodegeneration - multiple diseases, Prion disease, Renin secretion, T cell receptor signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Tuberculosis, VEGF signaling pathway, Wnt signaling pathway, cGMP-PKG signaling pathway 💬1件: 222 💬
78Rituximab combined with tacrolimus induction + tacrolimus maintenance
(D02994)		2件: Rituximab,
Tacrolimus		3件: Tacrolimus ,
Rituximab (D02994),
Tacrolimus 💬 		6件: MS4A1,
PPP3CA,
PPP3CB,
PPP3CC,
PPP3R1,
PPP3R2 💬 		34件: Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis, Axon guidance, B cell receptor signaling pathway, C-type lectin receptor signaling pathway, Calcium signaling pathway, Cellular senescence, Dopaminergic synapse, Glucagon signaling pathway, Glutamatergic synapse, Hematopoietic cell lineage, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Lipid and atherosclerosis, Long-term potentiation, MAPK signaling pathway, Natural killer cell mediated cytotoxicity, Oocyte meiosis, Osteoclast differentiation, Oxytocin signaling pathway, PD-L1 expression and PD-1 checkpoint pathway in cancer, Pathways of neurodegeneration - multiple diseases, Prion disease, Renin secretion, T cell receptor signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Tuberculosis, VEGF signaling pathway, Wnt signaling pathway, cGMP-PKG signaling pathway 💬1件: 222 💬
79Rituximab Infusion
(D02994)		1件: Rituximab1件: Rituximab (D02994) 💬 1件: MS4A1 💬 1件: Hematopoietic cell lineage 💬3件: 13, 222, 223 💬
80Rituximab Injection
(D02994)		1件: Rituximab1件: Rituximab (D02994) 💬 1件: MS4A1 💬 1件: Hematopoietic cell lineage 💬3件: 11, 35, 222 💬
81Rituximab IT
(D02994)		1件: Rituximab1件: Rituximab (D02994) 💬 1件: MS4A1 💬 1件: Hematopoietic cell lineage 💬1件: 13 💬
82Rituximab IV
(D02994)		1件: Rituximab1件: Rituximab (D02994) 💬 1件: MS4A1 💬 1件: Hematopoietic cell lineage 💬1件: 13 💬
83Rituximab konsentrat til infusjonsvaeske oppløsning 10 mg/ml
(D02994)		1件: Rituximab1件: Rituximab (D02994) 💬 1件: MS4A1 💬 1件: Hematopoietic cell lineage 💬1件: 13 💬
84Rituximab MabThera
(D02994)		1件: Rituximab1件: Rituximab (D02994) 💬 1件: MS4A1 💬 1件: Hematopoietic cell lineage 💬1件: 46 💬
85Rituximab plus methylprednisolone
(D02994)		2件: Methylprednisolone,
Rituximab		3件: Methylprednisolone ,
Methylprednisolone acetate ,
Rituximab (D02994) 💬 		2件: MS4A1,
NR3C1 💬 		2件: Hematopoietic cell lineage, Neuroactive ligand-receptor interaction 💬1件: 63 💬
86Rituximab(RTX)
(D02994)		1件: Rituximab1件: Rituximab (D02994) 💬 1件: MS4A1 💬 1件: Hematopoietic cell lineage 💬1件: 13 💬
87Rituximab, Cyclophosphamide, and Corticosteroids
(D02994)		2件: Cyclophosphamide,
Rituximab		3件: Cyclophosphamide ,
Rituximab (D02994),
Cyclophosphamide 💬 		1件: MS4A1 💬 1件: Hematopoietic cell lineage 💬1件: 222 💬
88Rituximab, Mabthera
(D02994)		1件: Rituximab1件: Rituximab (D02994) 💬 1件: MS4A1 💬 1件: Hematopoietic cell lineage 💬1件: 53 💬
89Rituximab, MTX, folic acid
(D02994)		2件: Folic acid,
Rituximab		3件: Folic acid ,
Rituximab (D02994),
Folate sodium 💬 		1件: MS4A1 💬 1件: Hematopoietic cell lineage 💬1件: 46 💬
90Rituximab, observational study amon patients with active RA
(D02994)		1件: Rituximab1件: Rituximab (D02994) 💬 1件: MS4A1 💬 1件: Hematopoietic cell lineage 💬1件: 46 💬
91Rituximab-EU+ Rituximab-Pfizer x 2 Courses
(D02994)		1件: Rituximab1件: Rituximab (D02994) 💬 1件: MS4A1 💬 1件: Hematopoietic cell lineage 💬1件: 46 💬
92Rituximab-Pfizer
(D02994)		1件: Rituximab1件: Rituximab (D02994) 💬 1件: MS4A1 💬 1件: Hematopoietic cell lineage 💬1件: 46 💬
93Rituximab-Pfizer (PF-05280586) x 3 courses
(D02994)		1件: Rituximab1件: Rituximab (D02994) 💬 1件: MS4A1 💬 1件: Hematopoietic cell lineage 💬1件: 46 💬
94Rituximab-US + Rituximab-Pfizer x 2 Courses
(D02994)		1件: Rituximab1件: Rituximab (D02994) 💬 1件: MS4A1 💬 1件: Hematopoietic cell lineage 💬1件: 46 💬
95Rituximab/ Mabthera
(D02994)		1件: Rituximab1件: Rituximab (D02994) 💬 1件: MS4A1 💬 1件: Hematopoietic cell lineage 💬1件: 271 💬
96SAIT101 (proposed rituximab biosimilar)
(D02994)		1件: Rituximab1件: Rituximab (D02994) 💬 1件: MS4A1 💬 1件: Hematopoietic cell lineage 💬1件: 46 💬
97SAIT101 (rituximab biosimilar)
(D02994)		1件: Rituximab1件: Rituximab (D02994) 💬 1件: MS4A1 💬 1件: Hematopoietic cell lineage 💬1件: 46 💬
98Sequential treatment with rituximab and cladribine
(D02994)		2件: Cladribine,
Rituximab		2件: Cladribine ,
Rituximab (D02994) 💬 		2件: MS4A1,
RRM1 💬 		5件: Drug metabolism - other enzymes, Glutathione metabolism, Hematopoietic cell lineage, Purine metabolism, Pyrimidine metabolism 💬1件: 13 💬
99Single infusion of Rituximab
(D02994)		1件: Rituximab1件: Rituximab (D02994) 💬 1件: MS4A1 💬 1件: Hematopoietic cell lineage 💬1件: 222 💬
100Standard dose of rituximab
(D02994)		1件: Rituximab1件: Rituximab (D02994) 💬 1件: MS4A1 💬 1件: Hematopoietic cell lineage 💬1件: 49 💬
101The Standard Steroid Treatment, Plasma Exchange and rituximab
(D02994)		1件: Rituximab1件: Rituximab (D02994) 💬 1件: MS4A1 💬 1件: Hematopoietic cell lineage 💬1件: 85 💬